A similar approach, for the treatment of melanoma patients, using CDX-1401 combined with a neoantigen-based melanoma-poly-ICLC vaccine and a recombinant Flt3 Ligand (CDX-301) (NCT02129075). Here, FLT3LG is linked to melanoma.